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The challenge of finding new therapeutic 
avenues in soft tissue sarcomas
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Abstract 
Soft tissue sarcomas are rare malignancies of mesenchymal origin comprising about 1% of all adult cancers. Sys‑
temic therapies for locally advanced and metastatic disease have been restricted for decades to very few effective 
and approved agents such as doxorubicin and ifosfamide. However, new therapeutic avenues including new drug 
developments and registrations such as trabectedin, pazopanib and eribulin as well as numerous clinical trial options 
have recently enriched the therapeutic armamentarium in the treatment of patients with advanced soft tissue sar‑
comas. The challenges and pitfalls of finding such new therapeutic avenues in recent years for the treatment benefit 
of patients with soft tissue sarcomas will be presented in this chapter within the thematic series on “Challenges in 
Sarcoma”.
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Background
Soft tissue sarcomas (STS) are a rare group of tumors of 
mesenchymal origin comprising about 1% of all malig-
nancies in the adulthood. According to the 2013 updated 
World Health Organization classification STS repre-
sents a highly heterogeneous tumor entity of more than 
50 subtypes showing distinct histological, molecular 
and certainly clinical characteristics [1]. Conventional 
chemotherapy with doxorubicin and/or ifosfamide still 
represents the backbone of systemic treatment in the 
locally advanced and metastatic setting sequentially or in 
combination [2]. Since the early 1980’s several trials have 
been investigating the addition of other chemotherapeu-
tic drugs to doxorubicin in order to improve overall sur-
vival (OS). However, no statistically significant OS benefit 
could be demonstrated. Even in the European Organisa-
tion for Research and Treatment of Cancer (EORTC) 
Soft Tissue and Bone Sarcoma Group (STBSG) 62012 
phase III study including 455 patients treated either with 
single-agent doxorubicin or with a combination regimen 
of doxorubicin plus high-dose ifosfamide the primary 
endpoint, overall survival, could not be met. Although 
the overall response rate (ORR) was nearly doubled (27% 
vs 14%) and the progression-free survival (PFS) could 
be significantly prolonged in the combination arm (7.4 
vs 4.6  months), the doxorubicin plus ifosfamide combi-
nation did not lead to a statistically significant improve-
ment in OS (14.3 vs 12.8 months) even though showing 
far more toxicity than doxorubicin alone [3]. After more 
than 40 years of standard first-line anthracycline therapy 
olaratumab, a platelet-derived growth factor receptor 
alpha (PDGFRα) inhibitor, in combination with doxoru-
bicin raised hope for a new first-line therapeutic option 
for advanced STS patients [4]; however, results of the 
phase III study could not confirm the initially observed 
OS benefit. With the successful approval of trabect-
edin, pazopanib and eribulin for specific STS subtypes 
the treatment landscape in the clinical setting beyond 
first-line has been broadened and promising and well-
tolerated systemic treatment options can be offered to 
our patients [5–8]. However, the prognosis of advanced 
STS patients is still unfavorable [9, 10]; median OS has 
increased during the last few years but is still approxi-
mately 15–18  months. Hence, there is clearly an unmet 
need to aim for new avenues, innovative drugs and new 
treatment strategies in this disease [11].
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New therapeutic avenues
Several promising agents have been investigated in recent 
years in large, multicentre, international registration tri-
als. Few of them having proven efficacy were approved 
by the corresponding medical health authorities and 
reached marketing authorization. These registered com-
pounds and new therapeutic avenues will be presented in 
more detail divided into (1) first-line avenues, (2) beyond 
first-line avenues and (3) avenues in development.
First‑line avenues
Olaratumab is a recombinant human immunoglobulin G 
subclass (IgG1)-type monoclonal antibody that binds to 
PDGFRα. PDGFRα activation by its ligand regulates cell 
proliferation, differentiation and survival. Olaratumab 
has been investigated in a phase Ib/II trial (n = 133) rand-
omizing patients to a treatment with doxorubicin or dox-
orubicin combined with olaratumab. Not only PFS could 
be significantly prolonged by the addition of olaratumab 
(6.6 vs 4.1  months; HR 0.67; p = 0.0615), an improve-
ment in OS of 11.8  months (26.5 vs 14.7  months; HR 
0.46; p = 0.0003) could be detected in the combination 
arm for the treatment of locally advanced and metastatic 
STS [4]. Several limitations of the phase II trial had to be 
taken into account such as low patient numbers, possible 
favorable selection of histologies, unbalanced administra-
tion of olaratumab as maintenance therapy, etc. Toxicity 
has to be considered and outweighed against the uncer-
tainty of the effect and the high costs of the drug. Based 
on these results the European Medicines Agency (EMA) 
recommended the granting of a conditional marketing 
authorization for olaratumab. Unfortunately, the subse-
quent international, multicenter, phase III ANNOUNCE 
study (NCT02451943) could not confirm the phase II 
results. The study did not meet the primary endpoint 
of OS in either the overall population (HR 1.05; median 
20.4 vs 19.7  months for olaratumab plus doxorubicin 
vs doxorubicin plus placebo) or in the leiomyosarcoma 
sub-population (HR 0.95; median 21.6 vs 21.9  months 
for olaratumab plus doxorubicin vs doxorubicin plus pla-
cebo). Median PFS and ORR were reduced in patients 
who received the combination of olaratumab plus doxo-
rubicin (median PFS: 5.4 vs 6.8  months; ORR: 14% vs 
18.3%).
Another drug candidate which has been evaluated in 
the first-line treatment of STS was evofosfamide (TH-
302), an investigational prodrug which is activated at 
very low levels of oxygen only. Tumor hypoxia is a com-
mon phenomenon in many human solid tumors like 
STS. Therefore, the side effect profile is expected to be 
lower when compared to conventional ifosfamide, which 
is characterized by a relevant incidence of neuro- and 
nephrotoxicity especially when given in high doses. The 
completed phase III trial (NCT01440088) was a rand-
omized, open-label, global, multicenter, phase III study 
designed to assess the efficacy and safety of evofosfamide 
in combination with doxorubicin compared to doxoru-
bicin alone in previously untreated patients with locally 
advanced, unresectable or metastatic STS. A total of 640 
patients were randomized; the primary endpoint of the 
study was OS. The response rate was slightly better in 
the combination arm, 28.4% vs 18.3%, respectively. Dis-
appointingly, no significant difference in median OS and 
PFS could be detected with the combination of evofos-
famide and doxorubicin when compared with doxoru-
bicin single-agent, 18.4 vs 19 months (HR 1.06) and 6.3 
vs 6  months (HR = 0.85; p = 0.099), respectively. Inter-
estingly, a significant improvement in OS was reported 
in the subgroup (n = 34) of synovial sarcomas, 22 vs 
9 months (HR = 0.32), respectively, underlining the sen-
sitivity of this STS subentity to oxazaphosphorine-based 
chemotherapy [12]. The most common grade 3 or worse 
adverse events in both treatment groups were hemato-
logical, including anemia (150 [48%] of 313 patients in 
the doxorubicin plus evofosfamide group vs 65 [21%] of 
308 in the doxorubicin group), neutropenia (47 [15%] vs 
92 [30%]), febrile neutropenia (57 [18%] vs 34 [11%]), leu-
copenia (22 [7%] vs 17 [6%]), decreased neutrophil count 
(31 [10%] vs 41 [13%]), and decreased white blood cell 
count (39 [13%] vs 33 [11%]). Grade 3/4 thrombocyto-
penia was more common in the combination group (45 
[14%]) than in the doxorubicin alone group (4 [1%]), as 
was grade 3/4 stomatitis (26 [8%] vs 7 [2%]).
Unfortunately, the developmental story of both drug 
candidates illustrates how difficult it is to develop 
effective new treatment options in first-line therapy 
for advanced STS and that a doxorubicin-based regi-
men continuous to be the gold-standard even more 
than 40  years after its introduction into the treatment 
armamentarium.
Beyond first‑line avenues
After the registration of trabectedin in Europe in 2007 
and pazopanib in 2012 for advanced STS subtypes, the 
results of another practice-changing trial have been 
published in 2016. The efficacy and safety of Eribulin, 
an inhibitor of microtubule dynamics, has been evalu-
ated in comparison with dacarbazine in an international, 
multicenter, phase III trial. 450 patients with pretreated, 
locally advanced or metastatic leiomyosarcoma or adipo-
cytic sarcoma have been included. The inclusion of these 
two STS subtypes originated in a treatment benefit seen 
in these two strata in the previously conducted phase II 
trial by the EORTC/STBSG [13]. The primary endpoint 
OS was shown to be significantly improved by 2 months 
(13.5 vs 11.5  months; HR 0.77; p = 0.0169) in favor of 
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eribulin when compared to dacarbazine. In particular, 
subgroup analysis revealed an OS benefit in the liposar-
coma cohort. Median OS was reported to be 15.6 months 
in the eribulin group versus 8.4  months in the dacar-
bazine treatment arm (HR 0.511; p = 0.0006) [8]. Based 
on these results, EMA approved eribulin in 2016 for 
the treatment of adipocytic sarcomas in patients who 
received prior chemotherapy containing an anthracycline 
regimen.
Avenues in development
Aldoxorubicin, a tumor-targeted doxorubicin conjugate 
(with an acid sensitive linker), has been under investiga-
tion in recent years. The randomized phase II trial com-
pared efficacy and safety parameters of aldoxorubicin 
versus doxorubicin in the first-line setting. Aldoxoru-
bicin showed a significant prolongation of the PFS (5.6 
vs 2.7 months; p = 0.02) and the 6-months PFS rate (46% 
vs 23%; p = 0.02). Notably, no cardiotoxicity was docu-
mented in the patients treated with aldoxorubicin [14]. 
The subsequent phase III study (NCT02049905), how-
ever, investigated aldoxorubicin in the second-line set-
ting when compared to treatment at investigator’s choice 
(dacarbazine, pazopanib, gemcitabine plus docetaxel, 
doxorubicin, ifosfamide). The trial has been regularly 
closed after reaching the planned accrual of 433 patients. 
Aldoxorubicin was not able to demonstrate a statistically 
significant improvement regarding PFS as the primary 
study endpoint (4.1 vs 2.9 months; p = 0.087) revealing a 
negative study for the whole study population. However, 
in the subcohort of l-sarcomas (leiomyosarcomas and 
liposarcomas, 57.5%) aldoxorubicin could improve PFS 
(5.3 vs 2.9 months; p = 0.007) and the disease control rate 
(41.7 vs 27%; p = 0.016). Interestingly, cardiotoxicity was 
less documented in the aldoxorubicin arm compared to 
the conventional doxorubicin arm rendering this com-
pound an interesting alternative to conventional doxoru-
bicin [15]. Based on these favorable toxicity results, the 
company is planning to submit a new drug application for 
aldoxorubicin to the US Food and Drug Administration.
Palbociclib, a selective CDK4/CDK6-inhibitor, and DS-
3032b, a MDM2-inhibitor, have both been investigated 
for the treatment of well- and de-differentiated liposarco-
mas (WDLS/DDLS). Both targets act as important nega-
tive regulators of p53, a tumor suppressor gene. Several 
phase I and II trials have been reported and/or published 
so far [16–18]. Notably, palbociclib was associated with a 
favorable PFS rate of 66% (90% CI 51–100%) in patients 
with CDK4-amplified WDLS/DDLS who had progres-
sive disease despite systemic therapy (NCT01209598). 
However, no further phase II/III development has been 
undertaken so far with these compounds.
Selinexor, an oral selective inhibitor of nuclear exportin 
protein, has been studied in STS and bone sarcomas [19]. 
Promising results have been published for the treatment 
of DDLS in a phase I trial recently. Although no objec-
tive responses by RECIST 1.1 could be demonstrated, 17 
patients (33%) showed durable (≥ 4  months) stable dis-
eases (NCT01896505) [20]. Therefore, a seamless phase 
II/III trial named SEAL (NCT02606461) has been initi-
ated which is currently recruiting patients with DDLS 
in the phase III portion (n = 245) in order to learn more 
about the efficacy of selinexor in this specific STS cohort.
Carotuximab (TRC105) is currently under investiga-
tion for the treatment of angiosarcomas. TRC105 is a 
monoclonal antibody targeting endoglin (CD105) which 
is expressed by tumor cells in angiosarcomas and up-reg-
ulated by VEGF-inhibition [21]. Hence, TRC105 is able 
to suppress angiogenesis and might enhance the activity 
of bevacizumab or other tyrosine multi-kinase inhibitors 
such as pazopanib [22]. Based on this pathomechanism 
a phase Ib/II trial combining TRC105 with pazopanib 
(800  mg daily) has been conducted (NCT01975519). A 
tumor reduction could be documented in five angiosar-
coma patients; two of them had progressive disease on 
previous pazopanib therapy. Two patients with cutane-
ous angiosarcoma experienced a complete remission 
according to RECIST. Median PFS for the angiosarcoma 
patients was 12.9  months [23]. An adaptive population 
enrichment phase III trial (TAPPAS, NCT02979899) 
investigating the combination of carotuximab in combi-
nation with standard dose pazopanib compared to single-
agent pazopanib 800 mg daily in patients with advanced 
angiosarcomas is currently under recruitment [24].
The revival of therapeutic affectation of the immune 
system has revolutionized patient outcome in many 
solid tumors in the last few years, in particular in mela-
noma [25]. This Immunotherapy approach is currently 
also being evaluated in STS. The largest published clini-
cal phase II study has been performed by the Sarcoma 
Alliance for Research through Collaboration (SARC) 
study group. In total, 80 patients with STS and bone sar-
comas from 12 participating centers have been treated 
with the PD1-inhibitor pembrolizumab. The primary 
endpoint was the response rate. A response rate of 18% 
was reported for the 40 included STS patients. The het-
erogeneity of STS in terms of biology and response to 
systemic treatment could be confirmed once again by 
showing different response rates depending on sarcoma 
subtypes. A promising response rate of 40% was reported 
for the undifferentiated, pleomorphic sarcoma cohort. In 
contrast, only 5% of bone sarcoma patients experienced 
a tumor response [26]. Further work has to be done in 
order to clarify the role of immunotherapy in STS. In 
particular, investigating potential predictive markers on 
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a molecular level for suggested differences in treatment 
sensitivity and evaluating the optimal treatment com-
binations of checkpoint inhibitors with chemotherapy, 
radiotherapy or targeted treatment options would be of 
major interest.
Commentary summary
What lessons have we learnt in drug development for 
sarcomas in the last few years? Since the early 1970’s sys-
temic therapies for locally advanced and metastatic soft 
tissue sarcomas have been restricted to very few effec-
tive and approved agents such as doxorubicin and ifosfa-
mide—and that hasn’t substantially changed until today. 
In 2007, trabectedin has been granted approval only in 
Europe and later in 2015 in the USA and other countries 
worldwide; it has turned out to be an effective compound 
especially for liposarcoma and leiomyosarcoma patients 
with the ability to stabilize the disease for long time peri-
ods. The next two registrations for STS, pazopanib and 
eribulin, have both been developed systematically in the 
phase II within the EORTC Soft Tissue and Bone Sar-
coma Group (STBSG). Activity has been studied in four 
different strata—leiomyosarcoma, liposarcoma, synovial 
sarcoma and other subtypes—and further development 
of the drug has only been undertaken in those strata 
where predefined EORTC activity criteria have been met. 
For example, for pazopanib no activity could be demon-
strated for the adipocytic stratum. Hence, liposarcoma 
patients were not included in the subsequent phase III 
PALETTE study and they are excluded from the registra-
tion label [7]. For eribulin, activity could only be demon-
strated in the liposarcoma and leiomyosarcoma strata. 
Hence, the subsequent phase III registration trial com-
paring eribulin to dacarbazine only included these two 
histologies [8]. This approach at least takes into account 
the perspective of disease groups and different histolo-
gies. In contrast, a number of large phase III trials in the 
last few years failed (ridaforolimus, palifosfamide, and 
evofosfamide); exactly because disease subgroups were 
not taken into account and all histologies were lumped 
together in one trial. More and more upcoming clinical 
trials address specific subtypes such as selinexor in lipo-
sarcoma or carotuximab in angiosarcoma and are leading 
to a more “personalization of sarcoma treatment”.
What new actions can we take from these lessons? 
What should we not do? We should only develop drugs 
with a clear scientific rationale and with clearly docu-
mented preclinical and early clinical activity. Empiri-
cal use of new drugs in different entities as it currently 
appears to be done in the immune-oncology field should 
be avoided. We should restrain from lumping together all 
histological subtypes in one trial. Rather to ensure that 
reimbursement follows licensing approvals, we should 
aim for meaningful treatment effects outweighing pos-
sible toxicities and drug costs and including patient 
reported outcome measures.
What pathway are we currently on and where might 
we consider where we could get to? We are definitely at 
a current breakpoint from classical drug development 
to more personalized strategies taking into account 
sequencing techniques with the possibility to identify 
patients for targeted therapies. However, we are still far 
away from designing a kind of personalized therapy for 
each of our patients. But with the number of registered 
drugs and the possibility to sequence them one after the 
other—even though we do not know which sequence is 
the best—we have been able to significantly prolong the 
overall survival for our advanced STS patients in the 
most recent years aiming to reach a 2 years median over-
all survival time.
Key points
• Patients suffering from sarcoma should be admit-
ted to sarcoma centers early in their disease course. 
Sarcoma treatment should be concentrated in des-
ignated institutions with a high expertise in sarcoma 
diagnostics and therapy. The European Reference 
Network (ERN) for rare adult solid cancers (EURA-
CAN) will certainly play a central role in this respect 
in the near future.
• Doxorubicin-based chemotherapy remains as the 
gold-standard treatment for locally advanced and 
metastatic STS patients in the first-line setting.
• Trabectedin, pazopanib and eribulin represent effica-
cious and well-tolerated treatment options beyond 
first-line therapy in several STS subtypes.
• Several promising new drug compounds (palbociclib, 
selinexor, carotuximab, etc.) and new therapeutic 
avenues such as immunotherapy are currently stud-
ied within ongoing clinical trials.
• Patients should preferably be treated within clinical 
trials, if available. International collaboration should 
be promoted in this matter.
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